Skip to main content

Advertisement

SpringerLink
Log in

Reduced Expression of Reelin (RELN) Gene Is Associated With High Recurrence Rate of Hepatocellular Carcinoma

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the world’s top five causes of cancer-related deaths. Current treatments available ameliorate HCC; however, current therapy fails to completely treat and prevent HCC, as shown by its high recurrence rate. Recently developed genome-wide gene-expression profile analyses can now robustly detect many candidate genes that are modified by HCC. Here we attempt to identify novel genes displaying altered gene expression profiles when comparing healthy tissue with HCC by means of a double-combination array previously developed.

Methods

Double-combination array analysis of gene expression profiles and single nucleotide polymorphism arrays were performed on each HCC tissue sample. Subsequently, samples from 48 HCC patients were subjected to quantitative real-time reverse transcription polymerase chain reaction and methylation-specific polymerase chain reaction.

Results

The reelin (RELN) gene was detected as a pertinent tumor suppressor gene by means of this method. Of the 48 clinical samples obtained, 34 (79.2%) displayed reduced RELN expression in tumor tissue, and the expression level of tumor tissues clearly reduced compared with that of corresponding normal tissues (P = 0.002). Eighteen (37.5%) of 48 tumor tissues were found to be hypermethylated on the RELN gene promoter. Moreover, analysis of clinical data revealed an inverse correlation between RELN expression and HCC recurrence.

Conclusions

The present study indicates that our in-house double-combination array is an effective and convenient technique in detecting novel genes with altered expression in disease. We suggest RELN is a key regulatory gene associated with the recurrence of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Arii S, Okamoto E, Imamura M. Registries in Japan: current status of hepatocellular carcinoma in Japan. Liver Cancer Study Group of Japan. Semin Surg Oncol. 1996;12:204–11.

    CAS  Google Scholar 

  3. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46.

    Article  CAS  PubMed  Google Scholar 

  4. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991;350:427–8.

    Article  CAS  PubMed  Google Scholar 

  5. Zhang X, Xu HJ, Murakami Y, et al. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res. 1994;54:4177–82.

    CAS  PubMed  Google Scholar 

  6. Yamada T, de Souza AT, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA. 1997;94:10351–5.

    Article  CAS  PubMed  Google Scholar 

  7. Zhang XK, Huang DP, Qiu DK, Chiu JF. The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors. Oncogene. 1990;5:909–14.

    CAS  PubMed  Google Scholar 

  8. Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994;54:3107–10.

    CAS  PubMed  Google Scholar 

  9. Hsu HC, Jeng YM, Mao TL, et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000;157:763–70.

    Article  CAS  PubMed  Google Scholar 

  10. Boix L, Rosa JL, Ventura F, et al. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology. 1994;19:88–91.

    Article  CAS  PubMed  Google Scholar 

  11. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467–70.

    Article  CAS  PubMed  Google Scholar 

  12. Lu YJ, Yang J, Noel E, et al. Association between large-scale genomic homozygosity without chromosomal loss and nonseminomatous germ cell tumor development. Cancer Res. 2005;65:9137–41.

    Article  CAS  PubMed  Google Scholar 

  13. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65:375–8.

    CAS  PubMed  Google Scholar 

  14. Kanda M, Nomoto S, Okamura Y, et al. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 2009;35:477–83.

    Article  CAS  PubMed  Google Scholar 

  15. Okamura Y, Nomoto S, Kanda M, et al. Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett. 2010;28:170–7.

    Article  Google Scholar 

  16. Nomoto S, Kanda M, Okamura Y, et al. Epidermal growth factor–containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol. 2010;17:923–32.

    Article  PubMed  Google Scholar 

  17. Rice DS, Curran T. Role of the reelin signaling pathway in central nervous system development. Annu Rev Neurosci. 2001;24:1005–39.

    Article  CAS  PubMed  Google Scholar 

  18. Tissir T, Goffnet AM. Reelin and brain development. Nat Rev Neurosci. 2003;4:496–505.

    Article  CAS  PubMed  Google Scholar 

  19. Sato N, Fukushima N, Chang R, Matsubayashi H, Goggins M. Microarrays and other new technologies. Gastroenterology. 2006;130:548–65.

    Article  CAS  PubMed  Google Scholar 

  20. Abdolmaleky HM, Cheng KH, Russo A, et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005;134:60–6.

    Google Scholar 

  21. Grayson DR, Jia X, Chen Y, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA. 2005;102:9341–6.

    Article  CAS  PubMed  Google Scholar 

  22. Robertson KD. DNA methylation and chromatin—unraveling the tangled web. Oncogene. 2002;21:5361–79.

    Article  CAS  PubMed  Google Scholar 

  23. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1:287–99.

    Article  CAS  PubMed  Google Scholar 

  24. Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev. 2005;25:383–97.

    Article  CAS  PubMed  Google Scholar 

  25. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104:1266–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Surgery II, Graduate School and Medicine, University of Nagoya, Nagoya, Japan

    Yukiyasu Okamura MD, Shuji Nomoto MD, PhD, Mitsuro Kanda MD, Masamichi Hayashi MD, Yoko Nishikawa, Tsutomu Fujii MD, PhD, Hiroyuki Sugimoto MD, PhD, Shin Takeda MD, PhD & Akimasa Nakao MD, PhD

Authors
  1. Yukiyasu Okamura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuji Nomoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitsuro Kanda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masamichi Hayashi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoko Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsutomu Fujii MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyuki Sugimoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shin Takeda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akimasa Nakao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuji Nomoto MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okamura, Y., Nomoto, S., Kanda, M. et al. Reduced Expression of Reelin (RELN) Gene Is Associated With High Recurrence Rate of Hepatocellular Carcinoma. Ann Surg Oncol 18, 572–579 (2011). https://doi.org/10.1245/s10434-010-1273-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1273-z

Keywords

Search

Navigation